A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Classic Hodgkin's Lymphoma Clinical Trial

Official title:
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus a Placebo Plus ICE Regimen in Classic Hodgkin's Lymphoma Patients With First-line Standard Chemotherapy Failure

Status Recruiting

Clinical Trial Summary

This phase III trial studies the side effects of sintilimab to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with classic Hodgkin lymphoma that does not respond to first-line standard chemotherapy.

Clinical Trial Description

randomized, double-blind, two arms , multicenter ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04044222
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact	Ronghua Zhang
Phone	15267110561
Email	ronghua.zhang@innoventbio.com
Status	Recruiting
Phase	Phase 3
Start date	October 21, 2019
Completion date	December 31, 2024

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05518318` - GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)	Phase 3